Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Reply to S. Pauwels et al.

Folkerd EJ, Dixon JM, A' Hern RP, Dowsett M.

J Clin Oncol. 2013 Feb 1;31(4):509-10. No abstract available.

2.

Aromatase inhibition in obese women: how much is enough?

Ligibel JA, Winer EP.

J Clin Oncol. 2012 Aug 20;30(24):2940-2. doi: 10.1200/JCO.2012.43.7244. Epub 2012 Jul 16. No abstract available.

3.

Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors.

Pauwels S, Lintermans A, Neven P, Verhaeghe J, Jans I, Billen J, Vanderschueren D, Vermeersch P.

J Clin Oncol. 2013 Feb 1;31(4):509. doi: 10.1200/JCO.2012.46.2622. Epub 2012 Dec 26. No abstract available.

4.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

5.

Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.

Bajetta E, Zilembo N, Bichisao E.

J Clin Oncol. 2002 Jul 1;20(13):3039-40; author reply 3040. No abstract available.

PMID:
12089238
6.

Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.

Dowsett M, Lønning PE.

Oncology. 1997;54 Suppl 2:11-4. Review.

PMID:
9394854
7.

Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.

Smith IE, Norton A.

Breast Cancer Res Treat. 1998;49 Suppl 1:S67-71; discussion S73-7. Review. No abstract available.

PMID:
9797020
8.

Aromatase inhibitors and calcium absorption in early stage breast cancer.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE.

Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.

9.
10.

Use of aromatase inhibitors in breast carcinoma.

Santen RJ, Harvey HA.

Endocr Relat Cancer. 1999 Mar;6(1):75-92. Review.

12.

[Evolvement of hormone therapy for breast cancer. Florence, March 14, 2001].

Longo F, Mansueto G.

Tumori. 2001 May-Jun;87(3):A6-14. Italian. No abstract available.

PMID:
11505951
13.

Intratumoral aromatase model: the effects of letrozole (CGS 20267).

Brodie A, Lu Q, Yue W, Wang J, Liu Y.

Breast Cancer Res Treat. 1998;49 Suppl 1:S23-6; discussion S33-7.

PMID:
9797014
14.

The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.

Frassoldati A, Guarneri V, Conte P.

Cancer Biol Ther. 2009 Aug;8(15):1456-8. Epub 2009 Aug 5. No abstract available.

PMID:
19617703
15.

New aromatase inhibitors in the treatment of advanced breast cancer.

Crucitta E, Lorusso V, Attolico M, Sambiasi D, Mazzei A, De Lena M.

Int J Oncol. 2000 Nov;17(5):1037-41. Review.

PMID:
11029510
16.

Anastrozole (Arimidex).

Wilkinson K.

Clin J Oncol Nurs. 2004 Feb;8(1):87-8. Review. No abstract available.

PMID:
14983769
17.

[Anastrozolo: intracellular anti-aromatase activity and pharmacologic interactions. Satellite Symposium AIOM 1999 - Roma].

Longo F, Mansueto G.

Tumori. 1999 Nov-Dec;85(6):A19-25. Italian. No abstract available.

PMID:
10774583
18.

Aromatase inhibitors: a dose-response effect?

Smith IE.

Endocr Relat Cancer. 1999 Jun;6(2):245-9. Review. No abstract available.

19.

Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.

Stanway SJ, Palmieri C, Stanczyk FZ, Folkerd EJ, Dowsett M, Ward R, Coombes RC, Reed MJ, Purohit A.

Anticancer Res. 2011 Apr;31(4):1367-72.

PMID:
21508387
20.

New breast cancer drug.

Brink S.

US News World Rep. 2001 Dec 24;131(26):52. No abstract available.

PMID:
11793594
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk